CLINICAL_TRIALS
trial_result
· 2022-08-19
Clinical Trial Update: A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine [Phase 3]
Summary
Phase 3 trial update for galcanezumab in episodic migraine has completed; results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Episodic Migraine | Phase 3 | Status: COMPLETED | Results posted: 2022-08-19